Influenza & Respiratory

 

 

This event will tackle the latest issues affecting vaccines for respiratory diseases including influenza, TB, RSV and MERS to stimulate the industry to develop more effective vaccines. Ensure you use this event to make people aware of your expertise around key topics such as universal and seasonal flu, maternal immunization and pandemic preparedness.

 

Who Attends

 

• Pharma
• Biotech
• National and International Government
• Non-Profit Organizations
• Academics And Research Institutions

 

Job Titles

 

• CEO / CSO / COO
• CMO / Head of Scientific Affairs
• Head of Influenza
• Head of Infectious Disease
• Head of R&D
• Head of Regulatory Affairs
• Head of Manufacturing
• Head of Immunology

Who Should Sponsor?

 

• Platform Technology Providers
• Biotechs
• Big Pharma
• Logistics / Cold Chain

 

Influenza and Respiratory Vaccines, Tuesday 16 April 2019

Universal and Pandemic Influenza Vaccines

James Crowe
Influenza and Respiratory Vaccines
09:10

Universal flu: are we any closer to finding the “holy “grail”? The Grand Challenge

  • 100 years on from the most severe influenza pandemic in recorded history, what have we learnt that’s translational to a universal solution
  • The multifactorial challenges involved in bringing innovation and improvement to flu products by building more rapid capabilities
  • Newest research in universal influenza vaccines and their potential impact on the flu market
10:40

Networking Coffee Break

Dr Luc Gagnon
Influenza and Respiratory Vaccines
11:40

Cheetah Pace for Premium Vaccine Clinical Assay Development: FLU HA Case Study

Dr Sean Tucker
Influenza and Respiratory Vaccines
12:10

Ph2 oral vaccine for protection against influenza challenge in humans

Dr Sybil Tasker
Influenza and Respiratory Vaccines
12:25

Ph2 NasoVAX report, a replication-deficient adenovirus vector technology intranasally delivered

Dr Olga Pleguezuelos
Influenza and Respiratory Vaccines
12:40

FLU-v, a broad spectrum influenza vaccine: Efficacy and Immunogenicity

13:10

Networking Lunch & Poster Session

Dr Koert Stittelaar
Influenza and Respiratory Vaccines
14:40

Building further on Viroclinics Ferret model with novel insights: Transmission of HRSV in Immunocompromised ferrets

  • Demonstration of efficient transmission of human respiratory syncytial virus (HRSV) from immunocompromised ferrets to both immunocompromised and immunocompetent ferrets.
  • Research findings were collected by applying several assays including Sequencing, PCR, Virus Culture/Titration. Furthermore, histo pathological changes of respiratory tissues from donor and contact ferrets were demonstrated by standard and immunohistochemistry.
  • A high transmission rate of HRSV was found and more

RSV Vaccines

Gregory Glenn
Influenza and Respiratory Vaccines
15:10

Ph3 and beyond: The RSV F nanoparticle vaccine for infants via maternal immunization

Peter Kwong
Influenza and Respiratory Vaccines
15:40

Structural vaccinology for paramyxoviruses

16:10

Networking Coffee Break

Ilse Dieussaert
Influenza and Respiratory Vaccines
16:40

GSK’s RSV vaccine pipeline update

Dr Christopher Heery
Influenza and Respiratory Vaccines
17:10

Ongoing development of a novel vaccine for Respiratory Syncytial Virus

  • An overview of preclinical, phase 1 data and recent phase 2 results
  • Development aspects unique to RSV and immunologic correlates
  • Potential avenues for next steps in demonstrating vaccine efficacy and receiving regulatory approval
Jon Heinrichs
Influenza and Respiratory Vaccines
17:40

Sanofi Pasteur’s RSV prophylactic program

18:10

Chair’s Closing Remarks per co-lo and Close of Congress Day 2

18:15

Off-site Networking Drinks, Supported by Enesi Pharma

last published: 11/Apr/19 17:05

Influenza and Respiratory Vaccines, Wednesday 17 April 2019

Influenza and Respiratory Vaccines
09:00

Chair's opening remarks

Respiratory Infections Strategy & Control

Dr Christopher Petro
Influenza and Respiratory Vaccines
09:40

Dupilumab imprints a TH1/Type 1 response and enhances the efficacy of the acellular whooping cough vaccine in mice and infant baboons

Dr Tim Hirst
Influenza and Respiratory Vaccines
09:55

A new broad-spectrum vaccine against Streptococcus pneumoniae

Michael Schrader
Influenza and Respiratory Vaccines
09:55

MIMIX Flu, is a broadly protective, shelf-stable, self-administered influenza vaccine

10:40

Networking Coffee Break

12:30

Networking Lunch & Poster Session

DAY 3 AFTERNOON PLENARY OF CONGRESS: RENAISSANCE BALLROOM

Paul Offit
13:40

New lessons from old controversies

  • What have we learnt from previous vaccines failures to drive new vaccines forward?
  • Why is there is low uptake on currently available vaccines? E.g. HPV & influenza
  • Examples and case studies from: Lyme & Rota – what does this mean for future vaccine innovation and R&D?
Dr Saad Omer
14:55

A framework for a comprehensive maternal immunization platform

  • Evidence for current immunization recommendations
  • Maternal vaccines in development
  • The need for evidence-based interventions at the practice, provider, and patient levels to ensure higher vaccination levels
Dr Timothy Cooke
16:00

Chair Closing Remarks and End of Congress

last published: 11/Apr/19 17:05

Sign Up for Event Updates

Get Involved At World Vaccine Congress Washington

 

To Sponsor Or Exhibit

Marc Rhys-Evans
marc.rhys-evans@terrapinn.com
+44 20 7827 5945

 

 

 

To Register

Tayyab Abbasi
tayyab.abbasi@terrapinn.com
+44 20 7092 1210

 

 

 

Press Relations

Karina Kusova
karina.kusova@terrapinn.com
+44 20 7092 1071